^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Solid Tumor
    Drug:relatlimab (BMS-986016) (LAG-3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

    Excerpt:
    Have metastatic or locally advanced mismatch repair deficient/MSI-H disease.
    Trial ID:
    NCT03607890